Repository logo
 
Publication

Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors, 2014-2015

2016-08Journal article Open access
Simple item page
dc.contributor.authorHurt, Aeron C.
dc.contributor.authorBesselaar, Terry G.
dc.contributor.authorDaniels, Rod S.
dc.contributor.authorErmetal, Burcu
dc.contributor.authorFry, Alicia
dc.contributor.authorGubareva, Larisa
dc.contributor.authorHuang, Weijuan
dc.contributor.authorLackenby, Angie
dc.contributor.authorLee, Raphael T.C.
dc.contributor.authorLo, Janice
dc.contributor.authorMaurer-Stroh, Sebastian
dc.contributor.authorNguyen, Ha T.
dc.contributor.authorPereyaslov, Dmitriy
dc.contributor.authorRebelo-de-Andrade, Helena
dc.contributor.authorSiqueira, Marilda M.
dc.contributor.authorTakashita, Emi
dc.contributor.authorTashiro, Masato
dc.contributor.authorTilmanis, Danielle
dc.contributor.authorWang, Dayan
dc.contributor.authorZhang, Wenqing
dc.contributor.authorMeijer, Adam
dc.date.accessioned2017-03-07T16:09:55Z
dc.date.issued2016-08
dc.description.abstractThe World Health Organization (WHO) Collaborating Centres for Reference and Research on Influenza (WHO CCs) tested 13,312 viruses collected by WHO recognized National Influenza Centres between May 2014 and May 2015 to determine 50% inhibitory concentration (IC50) data for neuraminidase inhibitors (NAIs) oseltamivir, zanamivir, peramivir and laninamivir. Ninety-four per cent of the viruses tested by the WHO CCs were from three WHO regions: Western Pacific, the Americas and Europe. Approximately 0.5% (n = 68) of viruses showed either highly reduced inhibition (HRI) or reduced inhibition (RI) (n = 56) against at least one of the four NAIs. Of the twelve viruses with HRI, six were A(H1N1)pdm09 viruses, three were A(H3N2) viruses and three were B/Yamagata-lineage viruses. The overall frequency of viruses with RI or HRI by the NAIs was lower than that observed in 2013-14 (1.9%), but similar to the 2012-13 period (0.6%). Based on the current analysis, the NAIs remain an appropriate choice for the treatment and prophylaxis of influenza virus infections.pt_PT
dc.description.versioninfo:eu-repo/semantics/publishedVersionpt_PT
dc.identifier.citationAntiviral Res. 2016 Aug;132:178-85. doi: 10.1016/j.antiviral.2016.06.001. Epub 2016 Jun 3pt_PT
dc.identifier.doi10.1016/j.antiviral.2016.06.001pt_PT
dc.identifier.issn0166-3542
dc.identifier.urihttp://hdl.handle.net/10400.18/4549
dc.language.isoengpt_PT
dc.peerreviewedyespt_PT
dc.publisherElsevier Masson/ International Society for Antiviral Researchpt_PT
dc.relation.publisherversionhttp://www.sciencedirect.com/science/article/pii/S0166354216302169pt_PT
dc.rights.urihttp://creativecommons.org/licenses/by-nc/4.0/pt_PT
dc.subjectAntiviral Resistancept_PT
dc.subjectGlobal Analysispt_PT
dc.subjectInfluenza Viruspt_PT
dc.subjectNeuraminidase Inhibitorspt_PT
dc.subjectOseltamivirpt_PT
dc.subjectReduced Susceptibilitypt_PT
dc.subjectResistência aos Antimicrobianospt_PT
dc.titleGlobal update on the susceptibility of human influenza viruses to neuraminidase inhibitors, 2014-2015pt_PT
dc.typejournal article
dspace.entity.typePublication
oaire.citation.endPage185pt_PT
oaire.citation.startPage178-85pt_PT
oaire.citation.titleAntiviral Researchpt_PT
oaire.citation.volume132pt_PT
rcaap.rightsopenAccesspt_PT
rcaap.typearticlept_PT

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors.pdf
Size:
1.35 MB
Format:
Adobe Portable Document Format
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

DDI - Artigos em revistas internacionais